UNSPSC 51112022: Ibrutinib

A type of kinase inhibitor

UNSPSC 51112022 Ibrutinib is a Commodity code identifying a specific pharmaceutical product — a tyrosine kinase inhibitor used in oncology and hematology treatment — that state and local health agencies procure through pharmacy benefit programs, group purchasing organizations, and direct contracting arrangements. The Texas Health and Human Services Commission's April 2026 Request for Information (RFI) on Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions signals that at least some state health systems are evaluating alternative supply-chain models that bypass traditional pharmacy benefit managers and wholesalers to source specialty pharmaceuticals like ibrutinib directly from manufacturers. The scope of work under this code spans the sourcing, contracting, and fulfillment of ibrutinib tablets or capsules for state employee health plans, Medicaid programs, and other covered populations, with issuing bodies typically including state health and human services departments managing pharmacy benefits.

Recent activity is sparse and concentrated in Texas, where the HHS Commission posted an RFI (HHS0017013) on April 3, 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs. The RFI signals early-stage strategic exploration rather than an immediate procurement opportunity — it requests information about vendors' capacity to negotiate net-pricing agreements and fulfill volume requirements outside traditional PBM and GPO channels, with no award value, budget, or formal evaluation criteria specified. The state intends to use vendor responses to design subsequent formal solicitations. Geographic spread and repeat-buyer activity under this Commodity code are not evident from the available source material; ibrutinib procurement remains a specialized function within state pharmacy benefit administration with limited visibility in public records.